Beta-blockers and antithrombotic treatment for secondary prevention after acute myocardial infarction Towards an understanding of factors influencing clinical practice
European Heart JournalPublished 1 January 1998Open access
K Woods
Citations60
SJR quartileQ1
SJR score4.99
SNIP8.87
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
There is persisting low use of beta-blocker secondary prophylaxis, particularly in the elderly and in women, not attributable to perceived contraindications or intolerance, despite shared trials evidence.
Abstract
There is persisting low use of beta-blocker secondary prophylaxis, particularly in the elderly and in women, not attributable to perceived contraindications or intolerance. Considerable regional variations persist despite shared trials evidence. Discharge treatment strongly influences long-term medication.
Keywords
Medicine
Progress in Cardiovascular DiseasesBeta blockade during and after myocardial infarction: An overview of the randomized trials
3,239 Citations1985Salim Yusuf, Richard Peto +3 more
The aim has been not only to review the 65-odd randomized beta blocker trials but also to demonstrate that when many randomized trials have all applied one general approach to treatment, it is often not appropriate to base inference on individual trial results.
New England Journal of MedicineTimolol-Induced Reduction in Mortality and Reinfarction in Patients Surviving Acute Myocardial Infarction
1,656 Citations1981The Norwegian Multicenter Study Group
It is concluded that long-term treatment with timolol in patients surviving acute myocardial infarction reduces mortality and the rate of reinfarction.
New England Journal of MedicineKnowledge and Practices of Generalist and Specialist Physicians Regarding Drug Therapy for Acute Myocardial Infarction
388 Citations1994John Z. Ayanian, Paul J. Hauptman +4 more
Internists and family practitioners are less aware of or less certain about key advances in the treatment of myocardial infarction than are cardiologists, underscoring the need to improve the dissemination of information from clinical trials to generalist physicians, particularly if they are to have an enlarged role in the evolving health care system.
HeartA British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).
307 Citations1996T J Bowker, Tim Clayton +6 more
There is considerable potential to reduce the risk of a further major ischaemic event in patients with established coronary disease by effective lifestyle intervention, the rigorous management of blood pressure and cholesterol, and the appropriate use of prophylactic drugs.
BMJDo women with acute myocardial infarction receive the same treatment as men?
214 Citations1994Katy Clarke, Denis Pereira Gray +2 more
Survival chances both in hospital and after discharge in women with acute myocardial infarction are reduced because they do not have the same opportunity for therapeutic intervention as men.
Medical Entomology and ZoologyBeta-Blockers in Clinical Practice
151 Citations1988J. M. Cruickshank, B. N. C. Prichard
Beta-Adrenoceptors, Coronary Risk and Primary Prevention, Pharmacokinetics and Hypertension, and Other Indications for Beta-Blockers.
Journal of the American College of CardiologyTreatment with beta-adrenergic blocking agents after myocardial infarction: From randomized trials to clinical practice
148 Citations1995Sami Viskin, Ilan Kitzis +7 more
The number of patients with myocardial infarction who are treated with beta-adrenergic blocking agents in dosages proved to be effective in preventing death after a heart attack was assessed to determine failure to prescribe beta-blockers to infarct survivors.
The LancetTranslation of clinical trials into practice: a European population-based study of the use of thrombolysis for acute myocardial infarction
132 Citations1996European Secondary Prevention Study Group, K.L. Woods
It is confirmed that only about one-third of patients admitted to European hospitals with AMI receive a thrombolytic drug, and the lower use of throm bolysis in the elderly may be due to their under-representation in the clinical trials.
Journal of the American College of CardiologyTrends in the use of drag therapies in patients with acute myocardial infarction: 1988 to 1992
122 Citations1994Chris L. Pashos, Sharon‐Lise T. Normand +4 more
Current usage rates of thrombolytic therapy are lower than expected, but trends in usage rates for beta-blockers and calcium channel blockers reflect their increasing and decreasing approval, respectively.
BMJUse of secondary prophylaxis against myocardial infarction in the north of England.
62 Citations1991M Eccles, Colin Bradshaw
Secondary prophylaxis after myocardial infarction is practised haphazardly and should be offered to all patients who can tolerate it, after a trial period to assess any side effects of the drugs if necessary.
BMJAudit of secondary prophylaxis after myocardial infarction
26 Citations1994David L Whitford, A J Southern
The effectiveness of aspirin and s blockers in reducing morbidity and mortality after myocardial infarction is now established, but a study in the Northern region in 1991 showed that only 41% of patients with myocardia were discharged taking the optimal drugs.
European Journal of Clinical PharmacologyClinical trials versus clinical practice in the secondary prevention of myocardial infarction
24 Citations1994Ant nia Agust, J.M. Arnau +1 more
Clinical trials on the secondary prevention of ischaemic heart disease have had some influence on cardiologists' prescription habits, but a large underuse of efficacious drugs such as βAA and ASA is recorded, especially among the elderly and among those patients with more severe cardiovascular disease.
Clinical CardiologyImpact of clinical trials on the use of beta blockers after acute myocardial infarction and its relation to other risk indicators for death and 1‐year mortality rate
21 Citations1994Björn W. Karlson, Johan Herlitz +1 more
When simultaneously considering various risk indicators for death, prescription of beta blockers at discharge was associated with an increased rate of survival, and beta blockers were not prescribed at discharge for one‐third of survivors after AMI.
PubMedSecondary prevention of coronary heart disease in patients after acute myocardial infarction at the Soroka Medical Center.
3 Citations1992A. H. Rubowitz, Avi Porath
There was a considerable gap between recommendations in the medical literature and the quality of care provided to AMI patients with regard to medications prescribed by physicians for preventive medical therapy during the period of this study.